In addition to genetics, some people may also have a mutation in the BRCA1 gene, which causes breast cancer in women with this condition. This mutation is known as BRCA1-negative, and a woman with this type of cancer will have a higher risk of developing the disease than a woman without this mutation.
The stage of triple-negative breast cancer will determine the treatment options. If the tumor is small and not involving lymph nodes, a lumpectomy may be recommended. Depending on the size of the tumor and its spread to the lymph nodes, a patient may undergo radiation. The treatments may be associated with side effects, such as fatigue, pain, and mental fogginess. If there are no symptoms after surgery, the cancer may come back after treatment. In such cases, the patient may need additional imaging tests or a biopsy to determine the exact cause of the tumor.
The BCRF is one of the world’s largest private funders of breast cancer research, dedicating 35 percent of its funds to the treatment of triple-negative breast cancer. Its investigators have been involved in every major breakthrough in triple-negative breast cancer research, including the discovery of the genetic mutation that causes this cancer, development of PARP inhibitors, and testing of the drug currently approved for treatment of this type of disease. While many women who develop triple-negative breast cancer will not qualify for this treatment option, it will be useful for patients who are undergoing surgery or chemotherapy.
Several studies have found that women who carry the BRCA1 mutation have a higher risk of developing the disease. However, this genetic disorder has been associated with a greater risk of developing ovarian and breast cancer. Research has shown that women with this genetic mutation may be more vulnerable to chemotherapy treatments that affect DNA repair. Although there are currently no clinical trials to confirm this theory, the evidence suggests that patients with this type of cancer are more susceptible to chemotherapy.
Although the research results for immunotherapy in triple-negative breast cancer remain mixed, there are some encouraging results. Three trials of immunotherapy in women with triple-negative breast cancer were positive, and the results of these studies are consistent with earlier research. There are also numerous ongoing studies to clarify the role of immunotherapy in triple-negative breast cancer. In the largest study of triple-negative breast cancer patients, which included 1824 women, BRCA1 or BRCA2 mutations were found in 11 percent of patients. This percentage is lower than that of older patients.
In addition to BRCA, women with this genetic disorder may also be at a higher risk for developing breast cancer than those with other types of cancer. This increased risk has led to a lower mortality rate for carriers. It has also resulted in a higher cure rate for women with this condition compared to the general population. Even women with this genetic disorder should not rule out the possibility of developing breast cancer. It is important to know the risks associated with this genetic disorder and to seek medical advice accordingly.
